Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) major shareholder Mpm Oncology Impact Management purchased 25,300 shares of Sunesis Pharmaceuticals stock in a transaction dated Thursday, November 2nd. The stock was bought at an average cost of $2.59 per share, with a total value of $65,527.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Mpm Oncology Impact Management also recently made the following trade(s):

  • On Monday, November 6th, Mpm Oncology Impact Management bought 81,500 shares of Sunesis Pharmaceuticals stock. The shares were acquired at an average cost of $2.77 per share, with a total value of $225,755.00.

Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) opened at $2.80 on Wednesday. The company has a debt-to-equity ratio of -0.34, a current ratio of 1.84 and a quick ratio of 1.84. Sunesis Pharmaceuticals, Inc. has a 1 year low of $1.82 and a 1 year high of $4.45.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same period last year, the company earned ($0.62) EPS. equities research analysts forecast that Sunesis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/11/08/mpm-oncology-impact-management-purchases-25300-shares-of-sunesis-pharmaceuticals-inc-snss-stock.html.

A number of equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Cantor Fitzgerald reiterated a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research note on Thursday, July 27th. Finally, Cowen and Company reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Thursday, November 2nd.

Several hedge funds have recently made changes to their positions in SNSS. Wells Fargo & Company MN raised its stake in shares of Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals in the 2nd quarter valued at $208,000. Renaissance Technologies LLC raised its stake in shares of Sunesis Pharmaceuticals by 1.1% in the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after buying an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. raised its stake in shares of Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 68,212 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares in the last quarter. Institutional investors own 56.43% of the company’s stock.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Stock Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.